199 related articles for article (PubMed ID: 31445816)
1. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
[TBL] [Abstract][Full Text] [Related]
2. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
3. A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy.
Wang K; Tseng CY; Li Z; White C; Wang B; Levine BL; Fesnak AD
Cytotherapy; 2023 Dec; 25(12):1370-1379. PubMed ID: 37747394
[TBL] [Abstract][Full Text] [Related]
4. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
5. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
Hourd P; Ginty P; Chandra A; Williams DJ
Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
[TBL] [Abstract][Full Text] [Related]
6. Cell and gene therapy manufacturing capabilities in Australia and New Zealand.
O'Sullivan GM; Velickovic ZM; Keir MW; Macpherson JL; Rasko JEJ
Cytotherapy; 2019 Dec; 21(12):1258-1273. PubMed ID: 31806531
[TBL] [Abstract][Full Text] [Related]
7. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
Harrison RP; Zylberberg E; Ellison S; Levine BL
Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
[TBL] [Abstract][Full Text] [Related]
9. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
10. Bioprocessing automation in cell therapy manufacturing: Outcomes of special interest group automation workshop.
Ball O; Robinson S; Bure K; Brindley DA; Mccall D
Cytotherapy; 2018 Apr; 20(4):592-599. PubMed ID: 29452894
[TBL] [Abstract][Full Text] [Related]
11. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
12. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Srai JS; Badman C; Krumme M; Futran M; Johnston C
J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
[TBL] [Abstract][Full Text] [Related]
13. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
Myles L; Church TD
Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
[TBL] [Abstract][Full Text] [Related]
14. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
15. Towards Automated Manufacturing for Cell Therapies.
Smith D; Heathman TRJ; Klarer A; LeBlon C; Tada Y; Hampson B
Curr Hematol Malig Rep; 2019 Aug; 14(4):278-285. PubMed ID: 31254154
[TBL] [Abstract][Full Text] [Related]
16. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
17. Interfacing data science with cell therapy manufacturing: where we are and where we need to be.
Wang B; Chen RQ; Li J; Roy K
Cytotherapy; 2024 Apr; ():. PubMed ID: 38842968
[TBL] [Abstract][Full Text] [Related]
18. An Implementation Research Approach to Re-orient Health Supply Chains Toward an Equity Agenda in the COVID-19 Era.
Frisch MF; Scott KW; Binagwaho A
Ann Glob Health; 2021 Apr; 87(1):42. PubMed ID: 33977085
[TBL] [Abstract][Full Text] [Related]
19. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
[TBL] [Abstract][Full Text] [Related]
20. Developing a Blockchain-Based Supply Chain System for Advanced Therapies: Protocol for a Feasibility Study.
Lam C; van Velthoven MH; Meinert E
JMIR Res Protoc; 2020 Dec; 9(12):e17005. PubMed ID: 33315020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
